Insmed Incorporated (NASDAQ:INSM) Shares Sold by MPM Bioimpact LLC

MPM Bioimpact LLC cut its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 36.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 389,611 shares of the biopharmaceutical company's stock after selling 225,780 shares during the period. Insmed accounts for about 3.8% of MPM Bioimpact LLC's portfolio, making the stock its 4th largest holding. MPM Bioimpact LLC owned approximately 0.22% of Insmed worth $26,899,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in INSM. Steward Partners Investment Advisory LLC boosted its position in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the period. V Square Quantitative Management LLC boosted its position in shares of Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 248 shares during the period. Spire Wealth Management purchased a new position in shares of Insmed during the fourth quarter worth $47,000. Smartleaf Asset Management LLC boosted its position in shares of Insmed by 98.1% during the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 411 shares during the period. Finally, Venturi Wealth Management LLC purchased a new position in shares of Insmed during the fourth quarter worth $86,000.

Insmed Stock Down 0.2%

NASDAQ:INSM traded down $0.11 during trading hours on Monday, hitting $68.01. The company's stock had a trading volume of 516,777 shares, compared to its average volume of 2,112,488. The stock has a fifty day moving average of $71.57 and a 200-day moving average of $73.16. The stock has a market capitalization of $12.39 billion, a P/E ratio of -12.17 and a beta of 0.84. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.06) EPS. On average, equities analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. UBS Group lowered their price target on Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research report on Friday, May 9th. JPMorgan Chase & Co. increased their price objective on Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research note on Friday, February 7th. Truist Financial increased their price objective on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Stifel Nicolaus reduced their price objective on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research note on Friday, February 21st. Finally, Jefferies Financial Group started coverage on Insmed in a research note on Tuesday, May 13th. They issued a "buy" rating and a $105.00 price objective on the stock. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $94.63.

Insiders Place Their Bets

In related news, insider Martina M.D. Flammer sold 8,408 shares of the firm's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $67.81, for a total value of $570,146.48. Following the completion of the sale, the insider now owns 91,757 shares in the company, valued at $6,222,042.17. This trade represents a 8.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares of the company's stock, valued at approximately $27,079,091.58. The trade was a 5.31% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 150,559 shares of company stock valued at $11,056,634. 3.00% of the stock is currently owned by insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.